Literature DB >> 22042091

Cyanosis in a 9-month-old child after repair of total anomalous pulmonary venous return.

Heiner Latus1, Tarique Hussain, Thomas Krasemann, Gerald F Greil.   

Abstract

A 9-month-old girl presented with cyanosis after correction of total anomalous pulmonary venous return (TAPVR) to the coronary sinus in the neonatal period. During corrective surgery, the right superior vena cava (RSVC) was damaged and re-anastomosed to the right atrium. Echocardiography showed increased flow velocity in the pulmonary venous confluence. Therefore, pulmonary venous obstruction was suspected. However, subsequent cardiac MRI revealed a stenosed RSVC as well as a dilated left superior vena cava (LSVC) draining from the left innominate vein into the pulmonary venous confluence. The re-recruited LSVC drained deoxygenated blood into the systemic circulation, causing cyanosis. After uncomplicated placement of a stent in the narrowed RSVC and occlusion of the LSVC, transcutaneous saturations normalised immediately.

Entities:  

Mesh:

Year:  2011        PMID: 22042091     DOI: 10.1007/s00247-011-2244-7

Source DB:  PubMed          Journal:  Pediatr Radiol        ISSN: 0301-0449


  3 in total

1.  Reopening of persistent left superior caval vein after bidirectional cavopulmonary connections.

Authors:  L H Filippini; C Ovaert; D G Nykanen; R M Freedom
Journal:  Heart       Date:  1998-05       Impact factor: 5.994

2.  Total anomalous pulmonary venous connection: outcome of surgical correction and management of recurrent venous obstruction.

Authors:  J A Hyde; O Stümper; M J Barth; J G Wright; E D Silove; J V de Giovanni; W J Brawn; B Sethia
Journal:  Eur J Cardiothorac Surg       Date:  1999-06       Impact factor: 4.191

3.  Total anomalous pulmonary venous connection: an analysis of current management strategies in a single institution.

Authors:  Camille L Hancock Friesen; David Zurakowski; Ravi R Thiagarajan; Joseph M Forbess; Pedro J del Nido; John E Mayer; Richard A Jonas
Journal:  Ann Thorac Surg       Date:  2005-02       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.